Point of Care (PoC) Molecular Diagnostics Market to Exceed $2.5 Bn by 2024
Published Date: November 15, 2017 Author: Global Market Insights, Inc.
Point of Care (PoC) Molecular Diagnostics Market size is set to exceed USD 2.5 billion by 2024; according to a new research study published by Global Market Insights, Inc.
Increasing awareness regarding pre-disease diagnosis along with growing incidence of infectious diseases will drive point of care molecular diagnostics market growth. Growing R&D focused on reducing time required for molecular tests will further propel industry growth. However, long product development time and complex regulatory process will hamper the business acceleration.
Isothermal amplification technology should exhibit lucrative growth as they are used as an alternative to polymerase chain reaction. Thermocycling machines are not required in the use of this technology and it can mostly be performed with reduced time, greater accuracy and high throughput. The increased reliability of isothermal amplification will drive segment growth. The added benefit of constant temperature of amplification provides a high potential for simple integration of this technique in PoC devices.
Sequencing technology are poised to grow at the fastest pace as ongoing advancements and increase in sequencing throughput have considerably decreased both sequencing costs and time.
Browse key industry insights spread across 150 pages with 130 market data tables & 14 figures & charts from the report, “Point of Care (PoC) Molecular Diagnostics Market Size By Technology [Polymerase Chain Reaction (Real Time PCR, DNA/RNA Purification), In Situ Hybridization, Chips and Microarrays, Mass Spectrometry, Sequencing, Isothermal Amplification, Others], By Infectious Diseases (MRSA, Clostridium difficile, Vancomycin-resistant Enterococci, Carbapenem-Resistant Bacteria Testing, Flu, Respiratory Syncytial Virus, Candida, Tuberculosis and Drug-resistant TB, Meningitis, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HIV , Hepatitis C, Hepatitis B, HPV, Syphilis, Others), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Japan, China, India, South Korea, Malaysia, Thailand, Vietnam, Philippines, Australia, Brazil, Argentina, Mexico, South Africa, Nigeria, Egypt, Morocco, Saudi Arabia, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2017 – 2024” in detail along with the table of contents:
Point of care molecular diagnostics for Clostridium difficile will witness robust growth in the coming years. In the developed countries, Clostridium infection is the most common cause of nosocomial infectious diarrhea. Growing use of PoC test owing to feasibility, performance ease and acceptability will fuel demand.
Growing demand for accurate and inexpensive PoC tests for controlling sexually transmitted infections along with need for immediate patient diagnosis and treatment will drive point of care molecular diagnostics for Gonorrhea.
India point of care molecular diagnostics market is slated to experience rapid growth over the forecast years. Increasing burden of various infectious diseases such as HIV, Tuberculosis, Hepatitis and Influenza will stimulate demand. PoC diagnostic testing is at its nascent stage in the country with tests being available for certain diseases. The industry is anticipated to witness significant growth over the coming years.
Mexico point of care molecular diagnostics market will witness considerable growth over the forecast timeframe owing to the increasing focus to deliver low cost care to the patient’s home. Increasing volume of point of care molecular testing will further stimulate demand. Growing efforts to provide effective care for infectious diseases along with easy to use devices will augment industry expansion.
Some of the prominent industry players include Abbott, Sysmex, Roche, Bayer, Danaher, BioMerieux and Bio-Rad Laboratories. Presently, there are few companies operating in the industry, however, the rivalry will intensify in the coming years with the entry of new players. The industry participants adopt various strategic initiatives such as launching of new products, geographical expansion and acquisitions to consolidate their market position. For instance, in July 2017, OraSure Technologies received prequalification from WHO for its OraQuick HIV Self- Test. The company also recently entered into an agreement with Bill & Melinda Gates Foundation for reducing the price of the test in 50 developing countries. Both the aforementioned strategies would accelerate adoption and deployment of the test.
Point of Care (PoC) molecular diagnostics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2013 to 2024, for the following segments:
Point of Care (PoC) Molecular Diagnostics Market by Technology
- Polymerase Chain Reaction (PCR)
- Real Time PCR
- DNA / RNA Purification
- In Situ Hybridization
- Chips and Microarrays
- Mass Spectrometry
- Isothermal Amplification
Point of Care (PoC) Molecular Diagnostics Market by Infectious Diseases
- Clostridium difficile
- Vancomycin-resistant Enterococci
- Carbapenem-Resistant Bacteria Testing
- Respiratory Syncytial Virus
- Tuberculosis and Drug-resistant TB
- Gastro-intestinal Panel Testing
- Hepatitis C
- Hepatitis B
The above information is provided for the following regions/countries:
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia